Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers

Breast Cancer Research and Treatment

Volumn 101, Issue 3, 2007, Pages 305-315

  Ooe, Asako ^a   Kato, Kikuya ^b   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

CCT5; Docetaxel resistance; p53 Mutated tumors in human breast cancers; RGS3; YKT6

Indexed keywords

CHAPERONIN CONTAINING TCP1 SUBUNIT 5; DOCETAXEL; MESSENGER RNA; PROTEIN; PROTEIN P53; REGULATOR OF G PROTEIN SIGNALING 3 PROTEIN; SMALL INTERFERING RNA; SOLUBLE N ETHYLMALEIMIDE SENSITIVE FACTOR ATTACHMENT PROTEIN RECEPTOR PROTEIN YKT6; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR RESISTANCE; UPREGULATION; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE; CHEMOTHERAPY, ADJUVANT; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P53; GTP-BINDING PROTEINS; GTPASE-ACTIVATING PROTEINS; HUMANS; MOLECULAR CHAPERONES; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; R-SNARE PROTEINS; RNA, SMALL INTERFERING; TAXOIDS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846471634     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9293-x     Document Type: Article

References (37)

1. Piccart MJ, de Valeriola D, Dal Lago L et al (2005) Adjuvant chemotherapy in 2005: standards and beyond. Breast 14:439-445
2. Hudis C (2005) The best use of adjuvant chemotherapy: new drugs and new use of "old" drugs. Breast 14:570-575
3. Charfare H, Limongelli S, Purushotham AD (2005) Neoadjuvant chemotherapy in breast cancer. Br J Surg 92:14-23
4. Trudeau M, Sinclair SE, Clemons M, Breast Cancer Disease Site Group (2005) Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review. Cancer Treat Rev 31:283-302
5. O'Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20-29
6. Mauriac L, Debled M, MacGrogan G (2005) When will more useful predictive factors be ready for use? Breast 14:617-623
7. Sjostrom J, Blomqvist C, Heikkila P et al (2000) Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6:3103-3110
8. Palmeri S, Vaglica M, Spada S et al (2005) Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study. Oncology 68(4-6):438-445
9. Figgitt DP, Wiseman LR (2000) Docetaxel: an update of its use in advanced breast cancer. Drugs 59:621-651
10. Sjostrom J, Blomqvist C, von Boguslawski K et al (2002) The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 8:811-816
11. Buchholz TA, Davis DW, McConkey DJ et al (2003) Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 9:33-41
12. Miyoshi Y, Taguchi T, Kim SJ et al (2005) Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer 12:11-15
13. Shalli K, Brown I, Heys SD, Schofield AC (2005) Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 19:1299-1301
14. Egawa C, Miyoshi Y, Takamura Y et al (2001) Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 95:255-259
15. Im SA, Kim SB, Lee MH et al (2005) Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. Oncol Rep 14:481-487
16. Rouzier R, Rajan R, Wagner P et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315-8320
17. Chang JC, Wooten EC, Tsimelzon A et al (2005) Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23:1169-1177
18. Iwao-Koizumi K, Matoba R, Ueno N et al (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23:422-431
19. Learn PA, Yeh IT, McNutt M et al (2005) HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 103:2252-2260
20. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1:1029-1034
21. Aas T, Borresen AL, Geisler S et al (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814
22. Wurzburger RJ, Gupta R, Parnassa AP et al (2003) Use of GC clamps in DHPLC mutation scanning. Clin Med Res 1:111-118
23. Zhang L, Jia G, Li WM, Guo RF, Cui JT, Yang L, Lu YY (2004) Alteration of the ATM gene occurs in gastric cancer cell lines and primary tumors associated with cellular response to DNA damage. Mutat Res 557:41-51
24. Saito S, Matoba R, Kato K (2003) Adapter-tagged competitive PCR (ATAC-PCR) - a high-throughput quantitative PCR method for microarray validation. Methods 31:326-331
25. Elbashir SM, Harborth J, Weber K, Tuschl T et al (2002) Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26:199-213
26. Andersson J, Larsson L, Klaar S et al (2005) Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann Oncol 16:743-748
27. Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233-240
28. Iwao K, Matoba R, Ueno N et al (2002) Molecular classification of primary breast tumors possessing distinct prognostic properties. Hum Mol Genet 11:199-206
29. Taniguchi K, Takano T, Miyauchi A et al (2005) Differentiation of follicular thyroid adenoma from carcinoma by means of gene expression profiling with adapter-tagged competitive polymerase chain reaction. Oncology 69:428-435
30. Kurokawa Y, Matoba R, Nakamori S et al (2004) PCR-array gene expression profiling of hepatocellular carcinoma. J Exp Clin Cancer Res 23:135-141
31. Motoori M, Takemasa I, Yano M et al (2005) Prediction of recurrence in advanced gastric cancer patients after curative resection by gene expression profiling. Int J Cancer 114:963-968
32. Casalou C, Cyrne L, Rosa MR, Soares H (2001) Microtubule cytoskeleton perturbation induced by taxol and colchicine affects chaperonin containing TCP-1 (CCT) subunit gene expression in Tetrahymena cells. Biochim Biophys Acta 1522:9-21
33. Ludwig A, Dietel M, Lage H (2002) Identification of differentially expressed genes in classical and atypical multidrug-resistant gastric carcinoma cells. Anticancer Res 22:3213-3221
34. Bowman EP, Campbell JJ, Druey KM, Scheschonka A, Kehrl JH, Butcher EC (1998) Regulation of chemotactic and proadhesive responses to chemoattractant receptors by RGS (regulator of G-protein signaling) family members. J Biol Chem 273:28040-28048
35. Tatenhorst L, Senner V, Puttmann S, Paulus W (2004) Regulators of G-protein signaling 3 and 4 (RGS3, RGS4) are associated with glioma cell motility. J Neuropathol Exp Neurol 63:210-222
36. Ikeda M, Hirokawa M, Satani N (2001) Molecular cloning and characterization of a steroid receptor-binding regulator of G-protein signaling protein cDNA. Gene 273:207-214
37. Kluger HM, Kluger Y, Gilmore-Hebert M et al (2004) cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab Invest 84:320-331